Insulin degludec
- Generic Name
- Insulin degludec
- Brand Names
- Ryzodeg, Tresiba, Xultophy
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 844439-96-9
- Unique Ingredient Identifier
- 54Q18076QB
- Background
Insulin degludec is an ultra-long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promotes glucose metabolism. ...
- Indication
Insulin degludec is indicated to improve glycemic control in patients 1 year of age and older with diabetes mellitus.
- Associated Conditions
- Diabetes Mellitus, Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
- Associated Therapies
- -
Evaluation of Glycemic Control in Adults With Type 1 Diabetes When Switching to Insulin Degludec
- First Posted Date
- 2022-06-28
- Last Posted Date
- 2022-12-21
- Lead Sponsor
- prof dr Pieter Gillard
- Target Recruit Count
- 475
- Registration Number
- NCT05434559
- Locations
- 🇧🇪
University Hospital Antwerp, Wilrijk, Belgium
🇧🇪Universitaire Ziekenhuizen Leuven, Leuven, Belgium
A Study of Insulin Efsitora Alfa (LY3209590) Compared to Degludec in Adults With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time
- Conditions
- Interventions
- First Posted Date
- 2022-05-05
- Last Posted Date
- 2024-08-01
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 928
- Registration Number
- NCT05362058
- Locations
- 🇺🇸
NorCal Medical Research, Inc, Greenbrae, California, United States
🇺🇸Catalina Research Institute, LLC, Montclair, California, United States
🇺🇸East Coast Institute for Research, LLC, Jacksonville, Florida, United States
A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 2 Diabetes Currently Treated With Basal Insulin
- Conditions
- Interventions
- First Posted Date
- 2022-03-11
- Last Posted Date
- 2024-05-28
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 986
- Registration Number
- NCT05275400
- Locations
- 🇺🇸
Diabetes Associates Medical Group, Orange, California, United States
🇺🇸Rocky Mountain Clinical Research, Idaho Falls, Idaho, United States
🇺🇸SKY Clinical Research Network Group - Hall, Fayette, Mississippi, United States
Afrezza With Basal Combination (ABC): Afrezza® Combined With AID Pump or Insulin Degludec in Adults With Type 1 Diabetes
- First Posted Date
- 2022-02-17
- Last Posted Date
- 2024-10-18
- Lead Sponsor
- Mannkind Corporation
- Target Recruit Count
- 33
- Registration Number
- NCT05243628
- Locations
- 🇺🇸
Diabetes Treatment Center, Loma Linda University, Loma Linda, California, United States
🇺🇸Texas Diabetes and Endocrinology, Austin, Texas, United States
Basal Plus GLP1-ra on Glycemic Variability in CKD
- Conditions
- Interventions
- First Posted Date
- 2022-02-01
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Elaine Chow
- Target Recruit Count
- 95
- Registration Number
- NCT05218915
- Locations
- 🇭🇰
Prince of Wales Hospital, Sha Tin, Hong Kong
A Research Study Looking at How the Use of NovoPen® 6 for Treatment With Tresiba® & Fiasp® Affects the Blood Sugar Level in Patients With Type 1 Diabetes as Part of Local Clinical Practice
- Conditions
- Interventions
- First Posted Date
- 2021-10-06
- Last Posted Date
- 2024-09-30
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 411
- Registration Number
- NCT05069545
- Locations
- 🇧🇪
HUB - Hôpital Erasme, Bruxelles, Belgium
🇧🇪Imeldaziekenhuis - Bonheiden - Department of Endocrinology, Bonheiden, Belgium
🇧🇪Cliniques Universitaires Saint-Luc - Serv Endocrinologie - Diabétologie, Bruxelles, Belgium
A Research Study to Compare a New Weekly Insulin, Insulin Icodec, and an Available Daily Insulin, Insulin Degludec, Both in Combination With Mealtime Insulin in People With Type 1 Diabetes (ONWARDS 6)
- Conditions
- Interventions
- First Posted Date
- 2021-04-19
- Last Posted Date
- 2023-09-14
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 582
- Registration Number
- NCT04848480
- Locations
- 🇯🇵
Yuri Ono Clinic, Sapporo-shi, Hokkaido, Japan
🇬🇧Churchill Hospital, Oxford, United Kingdom
🇬🇧Lister Hospital, Stevenage, United Kingdom
A Research Study to Compare Two Types of Insulin, a New Insulin, Insulin Icodec and an Available Insulin, Insulin Degludec, in People With Type 2 Diabetes Who Have Not Used Insulin Before (ONWARDS 3)
- Conditions
- Interventions
- First Posted Date
- 2021-03-12
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 588
- Registration Number
- NCT04795531
- Locations
- 🇨🇳
Novo Nordisk Investigational Site, Taipei, Taiwan
🇺🇸Lakeview Clinical Research, LLC, Guntersville, Alabama, United States
🇺🇸American Clinical Trials, Buena Park, California, United States
A Research Study to Compare Two Types of Insulin, a New Weekly Insulin, Insulin Icodec and an Available Daily Insulin, Insulin Degludec, in People With Type 2 Diabetes Who Use Daily Insulin
- Conditions
- Interventions
- First Posted Date
- 2021-02-25
- Last Posted Date
- 2023-05-15
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 526
- Registration Number
- NCT04770532
- Locations
- 🇺🇦
Novo Nordisk Investigational Site, Ternopil, Ukraine
A Research Study to Compare a New Weekly Insulin, Insulin Icodec Used With DoseGuide App, and Daily Insulins in People With Type 2 Diabetes Who Have Not Used Insulin Before
- Conditions
- Interventions
- First Posted Date
- 2021-02-18
- Last Posted Date
- 2024-08-07
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 1085
- Registration Number
- NCT04760626
- Locations
- 🇺🇸
Cedar-Crosse Research Center, Chicago, Illinois, United States
🇬🇷Iatriko Psychicou Private Clinic, Athens, Greece
🇬🇷Korgiallenio - Benakio Hospital (Red Cross Hosp.), Athens, Greece
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.